Efficient and reproducible identification of mismatch repair deficient colon cancer: validation of the MMR index and comparison with other predictive models by unknown
Joost et al. BMC Clinical Pathology 2013, 13:33
http://www.biomedcentral.com/1472-6890/13/33RESEARCH ARTICLE Open AccessEfficient and reproducible identification of
mismatch repair deficient colon cancer: validation
of the MMR index and comparison with other
predictive models
Patrick Joost1,2*, Pär-Ola Bendahl3, Britta Halvarsson4, Eva Rambech3 and Mef Nilbert3,5Abstract
Background: The identification of mismatch-repair (MMR) defective colon cancer is clinically relevant for diagnostic,
prognostic and potentially also for treatment predictive purposes. Preselection of tumors for MMR analysis can be
obtained with predictive models, which need to demonstrate ease of application and favorable reproducibility.
Methods: We validated the MMR index for the identification of prognostically favorable MMR deficient colon
cancers and compared performance to 5 other prediction models. In total, 474 colon cancers diagnosed ≥ age 50
were evaluated with correlation between clinicopathologic variables and immunohistochemical MMR protein
expression.
Results: Female sex, age ≥60 years, proximal tumor location, expanding growth pattern, lack of dirty necrosis,
mucinous differentiation and presence of tumor-infiltrating lymphocytes significantly correlated with MMR defi-
ciency. Presence of at least 4 of the MMR index factors identified MMR deficient tumors with 93% sensitivity and
76% specificity and showed favorable reproducibility with a kappa value of 0.88. The MMR index also performed
favorably when compared to 5 other predictive models.
Conclusions: The MMR index is easy to apply and efficiently identifies MMR defective colon cancers with high
sensitivity and specificity. The model shows stable performance with low inter-observer variability and favorable
performance when compared to other MMR predictive models.
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Genomic destabilization is an intrinsic, tumor-promo-
ting feature in most cancer cells. In colon cancer this is
achieved through tumorigenic pathways related to
chromosomal instability, CpG island methylation and
mismatch repair (MMR) defects that cause microsatellite
instability (MSI) [1]. The identification of MMR defect-
ive tumors provides prognostic information and identi-
fies heritable cases linked to Lynch syndrome. MMR
defective tumors are typically located proximal to the* Correspondence: patrick.joost@med.lu.se
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reproduction in any medium, provided the orsplenic flexure and are overrepresented among young
patients (mean 45 years) in Lynch syndrome and older
patients (mean 75 years) in sporadic cases [2-7].
Morphologic characteristics of MMR deficient tumors in-
clude an expanding tumor growth pattern, poor and mu-
cinous differentiation, a solid/medullary growth pattern,
lack of “dirty necrosis” and lymphocytic reactions such as
peritumoral lymphocyte infiltration, Crohn-like reactions
and presence of tumor-infiltrating lymphocytes (TIL)
[6,8-10]. Increasing evidence suggests that the identification
of MMR deficient tumors provides clinically relevant infor-
mation, but universal MMR screening has not yet gained
widespread application in clinical practice [11-13].
Our study focuses on the 20% of the non-hereditary
colon cancers with somatic MLH1 promoter methylationtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gested poor response to 5-fluorouracil-based regimens
[11-18]. A prescreening procedure that identifies tumors
with a high likelihood of MMR deficiency could be clin-
ically valuable for institutions that have not implemented
universal assessment of MMR status. Several predictive
models aimed at identifying tumors with an increased
likelihood of MMR deficiency have been established
(Table 1) [19-24]. These models have predominantly fo-
cused on the identification of Lynch syndrome tumors,
whereas the MMR index and the RERtest6 model were
developed in series that had a substantial contribution
from sporadic MMR deficient tumors [20,24,25]. For
such models to be implemented in the routine histo-
pathologic work-up, the assessment should be easy to
apply, i.e. preferentially be based on factors that can be
evaluated on standard sections, and reproducible. We vali-
dated the MMR index in an independent series of 474
colon cancers and provide data on the reproducibility andTable 1 Summary of clinicopathologic features evaluated in t
Model (reference) MMR index [25] MsPath [19,23]
No. of variables 7 6
Sex Female -
Age (years) ≥60 <50
Tumor location Proximal Proximal
Growth pattern Expanding -






TIL ≥7 TIL/10 HPF ≥5 TIL/HPF
(10 HPFs searched)
Differentiation - Poorly differentiate







Scoring system No score, 7-factor index,
cut-off ≥4
Score: cut-off ≥1
Sensitivity 92.3% (4 features of 7) 93%




IHC (4 markers), BRAF
mutation
MSI (10 markers) an
IHC (4 markers);
validation study: MS
(5 markers) and IHC
(MLH1, MSH2), BRA
mutation
Abbreviations: HPF high-power field, IHC immunohistochemistry, LPF low-power field




All colon (n = 474) cancers from 462 patients (210 men
and 252 women) who underwent surgery at the Helsing-
borg Hospital, Sweden between 2002 and 2006 were eli-
gible for the study. None of the patients had a previous
colorectal cancer diagnosis. In order to minimize the
contribution from Lynch syndrome, patients diagnosed
<50 years of age were excluded. Synchronous colon can-
cers were identified in 12 patients. The study was ap-
proved by the Lund University ethics committee.
Histopathologic evaluation
All available hematoxylin and eosin (H&E) stained slides
were morphologically evaluated according to a standard-
ized protocol by two independent investigators (B.H.he different models to predict MMR deficiency









- Lack of -
a)
Any component Any component Amount in %
- - Amount in %
≥ 5TIL/HPF
(10 HPF searched)
≥2 TIL/mean of 5
HPF
≥4TIL/HPF
d - Well or poorly
differentiated
-










no score, ≥2 features present




96.9% (score ≥2.5) 92% (score 1) 78.0%




MSI (5 markers); validation
cohort only 1 marker if
age ≥75 years
MSI (4 markers) MSI (11
markers)
, MMR mismatch repair, MSI microsatellite instability, TIL tumor-infiltrating
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results as well as to the results from the other reviewer.
The evaluators considered invasive tumor components
and did not take intramucosal/early invasive tumor com-
ponents into account [8,26]. Tumor location was classi-
fied as proximal/distal in relation to the splenic flexure
[2]. Tumor stage was determined according to the
American Joint Cancer Committee/Union Internationale
Contre le Cancer (AJCC/UICC) staging system and the
grade according to the WHO system [27]. Mucinous/sig-
net-ring cell cancers were considered poorly differenti-
ated. Growth pattern was classified as expanding if a
continuous, rounded infiltration margin was found and
as infiltrating if invading foci were identified [10]. Dirty
necrosis was defined as the presence of cell detritus and
inflammatory cells within the glandular lumina and was
scored as present or absent [9]. A tumor was classified
as mucinous or signet-ring cell cancer if more than 50%
of the tumor area showed such differentiation [27]. Tu-
mors with mucinous/ signet-ring cell components that
encompassed 10-50% of the area but did not fulfill the
criteria for mucinous/signet-ring cell tumors were classi-
fied as having a mucinous/signet-ring cell component
[25]. TIL were identified on H&E-stained slides and de-
fined as intraepithelial lymphocytes between tumor cells;
they were scored as present if there were ≥7 TIL per 10
high-power fields (40×, field diameter 0.53 mm) [8,26].
Application of the MMR index
The MMR index includes the factors female sex, age
≥60 years, proximal tumor location, expanding growth
pattern, lack of dirty necrosis, any mucinous/signet-ring
cell differentiation (mucinous/signet-ring cell tumor or
mucinous/signet-ring cell component) in ≥10% of the
tumor area and presence of TIL. The index was applied
to all tumors in the series. As previously reported [25],
the presence of ≥4 factors was chosen as the cut-off limit
based on optimal sensitivity and specificity. All slides
were evaluated by B.H., In addition, 200 randomly se-
lected tumors were independently evaluated by P.J. for
the assessment of reproducibility. Complete data were
obtained for 189 tumors, which were included in the
final evaluation of inter-observer reproducibility.
Immunohistochemical analysis
Fresh 4-μm sections were immunohistochemically
stained using antibodies against MLH1 (clone G168-15,
1:50, BD PharMingen, San Diego, CA, USA or clone
ES05, 1:100, Dako, Glostrup, Denmark), PMS2 (clone
A16-4, 1:300, BD PharMingen), MSH2 (clone FE-11,
1:100, Calbiochem, La Jolla, CA, USA) and MSH6 (clone
EPR3945, 1:100; Epitomics, Burlingame, CA, USA) using
the EnVision™ (Dako, Glostrup, Denmark) detection kit
[28]. MMR protein expression was evaluated withoutknowledge of the results of the morphologic review and
was classified as retained (presence of nuclear staining)
or lost (loss of nuclear staining with retained staining in
stromal, inflammatory or non-neoplastic epithelial cells).
Comparison with other predictive models
The MMR index results were compared with those from
5 other predictive models (Table 1), i.e. MsPath [19,23],
PREDICT/simplified PREDICT [22], MSI probability
score [21] and RERtest6 [20,24] in 200 randomly se-
lected tumors, 20% (n = 40) of which were MMR
deficient.
Statistical analysis
For statistical calculations, the software package Stata
12.1 (StataCorp. 2012, College Station, TX, USA) was
used. The histopathologic variables were dichotomized
and assigned equal weights. The association between
MMR status and the other histopathologic factors was
analyzed by means of contingency tables and Fisher’s
exact test. Patients with any missing value were excluded
from the analysis (n = 24). A multiple logistic regression
model that contained the 7 dichotomized clinicopatho-
logic factors as covariates was fitted to determine the in-
dependent contribution of each factor at predicting
MMR deficiency. These effects were summarized as
odds ratios (OR) with 95% confidence intervals (CI). The
sensitivity and specificity of the MMR index were calcu-
lated by means of a receiver operating characteristic
(ROC) curve. Inter-observer variability was expressed
using the chance-corrected measure of agreement kappa.
The performance of the different models was evaluated
by calculating the sensitivity, specificity, positive predict-
ive value (PPV) and negative predictive value (NPV) and
area under the ROC curve (AUC).
Results
MMR deficiency, defined as immunohistochemical loss
of at least one MMR protein, was identified in 108/474
(22.8%) tumors. No tumors showed weak or reduced
MMR protein staining. The MMR deficient tumors pre-
dominantly developed in women (74.8%), in the prox-
imal colon (91.7%) and were diagnosed at a mean age of
76 (range 50–100) years (Table 2). MMR defects in-
volved MLH1/PMS2 in 93 tumors, PMS2 in 1, MSH2/
MSH6 in 5, MSH6 in 4, and MLH1/PMS2 and MSH6 in
5. This means that defects highly suggestive of Lynch
syndrome (mutations in MSH2 and MSH6) were identi-
fied in 14/474 (3%) cases.
Several morphologic features were overrepresented in
MMR deficient tumors in comparison with MMR profi-
cient tumors (Table 2). This applied to expanding growth
pattern (73.8% versus 7.6%), lack of dirty necrosis (80.6%
versus 26.1%), mucinous/signet-ring cell differentiation
Table 2 Distribution of clinicopathologic factors in relation to MMR status (n = 474)
Factor Frequency (%)
MMR deficient MMR proficient
Patients (n = 462) Total number 103 (22.3) 359 (77.7)
Sex (n = 462) Male 26 (25.2) 184 (51.3)
Female 77 (74.8) 175 (48.7)
Age (n = 462) Mean 76 74
Age ≥60 102 (99.0) 328 (91.4)
Tumors (n = 474) Total number 108 (22.8) 366 (77.2)
pT stage (n = 450) pT1 2 (1.9) 6 (1.7)
pT2 10 (9.6) 37 (10.7)
pT3 87 (83.7) 224 (64.8)
pT4 5 (4.8) 79 (22.8)
pN stage (n = 461) pN0 76 (73.1) 183 (51.2)
pN1 23 (22.1) 107 (30.0)
pN2 5 (4.8) 67 (18.8)
pM stage (n = 474) pM1 1 (0.9) 10 (2.7)
Differentiation (n = 474) Good/moderate 42 (38.9) 334 (91.3)
Poor/no 66 (61.1) 32 (8.7)
Location (n = 473) Proximal 99 (91.7) 173 (47.4)
Distal 9 (8.3) 192 (52.6)
Growth pattern (n = 459) Expanding 76 (73.8) 27 (7.6)
Infiltrating 27 (26.2) 329 (92.4)
Dirty necrosis (n = 467) Present 20 (19.4) 269 (73.9)
Absent 83 (80.6) 95 (26.1)
Mucin/signet-ring differentiation (n = 473) Present (>50%) 23 (21.3) 15 (4.1)
Present (10-50%) 50 (46.3) 81 (22.2)
Absent 35 (32.4) 269 (73.7)
TIL (n = 470) Present 72 (66.7) 61 (16.9)
Absent 36 (33.3) 301 (83.1)
Abbreviations: MMR mismatch repair, TIL tumor-infiltrating lymphocytes.
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16.9%). The strongest predictive indicators of MMR defi-
ciency were expanding growth pattern (OR 11.6; 95% CI
5.5-24.5), presence of TIL (OR 5.6; 95% CI 2.6-12.1), mu-
cinous/signet-ring cell differentiation (OR 3.0; 95% CI 1.3-
6.0) and lack of dirty necrosis (OR 3.0; 95% CI 1.3-7.0).
Inter-observer agreement was 90%, which corresponds to
a kappa value of 0.88. The kappa values for the individual
histopathologic markers were 0.78 for TIL, 0.94 for mu-
cinous/signet-ring cell components, 0.96 for lack of dirty
necrosis and 0.97 for expanding growth pattern.
The MMR index was applied in 438 patients from
whom complete data were available. In these patients,
the presence of ≥4 factors identified MMR deficient
colon cancers with 92.6% sensitivity and 75.5% specifi-
city, corresponding to an ROC curve with an AUC of
0.94 (95% CI, 0.91-0.96) (Figure 1). Comparison withother predictive models was performed in 200 randomly
selected tumors, in which the MMR index – applied
with a cut-off of ≥4 factors – resulted in an AUC of 0.83
(95% CI, 0.79-0.87) and identified MMR deficient tu-
mors with 97.5% sensitivity and 69% specificity. The fac-
tors expanding growth pattern, TIL, mucinous/signet-
ring cell differentiation and lack of dirty necrosis identi-
fied MMR deficient tumors with almost identical per-
formance as identified in the original report of the MMR
index [25]. The distribution of clinicopathologic features
evaluated by the other models is supplementary table
[see Additional file 1: Table S1]; the respective AUC
values were 0.81 for PREDICT, 0.80 for RERtest6, 0.70
for MsPath and 0.77 for the MSI probability score. Sen-
sitivities varied from 60% to 100% and specificities from
41% to 99% (Table 3). The performance of the MMR
index was similar to that of the PREDICT/simplified
Figure 1 Morphologic factors included in the MMR index. A) Expanding growth pattern (x5), B) Tumor-infiltrating lymphocytes (x40),
C) Mucinous differentiation (x10) and D) Dirty necrosis (x20). E) Receiver operating characteristic curve demonstrating sensitivity and specificity
for an increasing number of factors in the index. Area under the curve 0.94. The suggested cut-off point (≥4 factors) is marked by a red dot.
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model (p = 0.42), but was significantly better than that of
the MsPath model (p <0.0001) and the MSI probability
score model (p <0.0001 for a cut-off >1 and p <0.01 for
a cut-off >1.5).
Discussion
The strongest predictive indicators of MMR deficiency
were an expanding growth pattern (OR 11.6), presence
of TIL (OR 5.6), mucinous/signet-ring cell differentiation
(OR 3.0) and lack of dirty necrosis (OR 3.0) (Table 3). In
comparison to the series in which the MMR index was
established, the age groups studied differed somewhat,
but the histopathologic characteristics were observed at
similar frequencies, i.e. 59-89% in the former study and
67-81% in the present series [25]. The predictive valuesTable 3 Performance of the different prediction models for M
Model Sensitivity (%) Specifici








MSI probability score 100.0 45.




Abbreviations: AUC area under curve, MMR mismatch repair, MSI microsatellite instabof the individual factors partly differed, but when com-
bined into a MMR index, presence of ≥4 of the factors
identified MMR defective tumors with similar sensitivity
(93%) and specificity (75%) in the sample sets. Reprodu-
cibility was demonstrated through independent and
blinded evaluation by two reviewers who identified
MMR deficient tumors with a kappa value of 0.88.
Hence, the model demonstrates stable performance, fa-
vorable prediction and is quick, cheap and easy to apply.
When compared with 5 other predictive models, the
MMR index demonstrated better performance than the
RERtest6 [20,24], MsPath [19,23] and the MSI probabil-
ity score [21] models and comparable performance to
the PREDICT/simplified PREDICT models [22] (Table 3).
The MsPath, PREDICT and MSI probability scores all
identified MMR deficient tumors with an equallyMR (n = 200)
ty (%) PPV (%) NPV (%) AUC
8 44.3 99.1 0.83
3 41.3 98.2 0.81
0 40.4 98.1 0.80
6 29.6 100.0 0.70
6 31.5 100.0 0.73
3 35.8 98.9 0.77
4 96.0 90.8 0.80
ility, NPV negative predictive value, PPV positive predictive value.
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RERtest6 model was clearly insufficient (60%) in our co-
hort. The MMR index identified 39/40 MMR deficient
tumors and would have prompted the evaluation of
MMR status in another 50 MMR proficient tumors. The
number of MMR proficient tumors that would be in-
cluded in testing with retained sensitivity was 54 for the
PREDICT model, but it was considerably higher for the
MSI probability score model (n = 70) and the MsPath
(n = 95) model. With exception of the RERtest6 model,
these algorithms have primarily been developed for the
identification of Lynch syndrome tumors [21-23]. The
MsPath, PREDICT and MSI probability score models
therefore include age <50 years as one of the predictive
variables, which means that comparison with the MMR
index in our study was suboptimal given that the study
only included cases diagnosed after age 50. The
RERtest6 model was, however, developed without age re-
striction and has also been validated in independent
tumor samples [20,24]. In our series, the RERtest6
model showed a high specificity but a low sensitivity;
only 1 tumor that had been identified as MMR deficient
was a false-positive, but 16/40 MMR deficient tumors
escaped detection [see Additional file 1: Table S1].
MMR testing is commonly requested without prior se-
lection in the 5% of colon cancers that develop before
age 50 [29-31]. Our study thus focused on patients
≥50 years of age, 23% of whom had MMR deficient
colon cancers with loss of MLH1/PMS2 in 86% of the
cases. The consistent silencing of MLH1 through pro-
moter methylation has been suggested to lead to more
pronounced histopathologic features than the variable
MMR gene defects observed in Lynch syndrome tumors
[6,15,32,33]. Despite our focus on a cohort over the age
of 50, we identified immunohistochemical losses (of
MSH2 and/or MSH6) suggestive of Lynch syndrome in
3% of the tumors. In particular, the contribution from
MSH6 was substantial. MSH6 mutations have been
linked to an overall lower risk of colon cancer, less strik-
ing family history, higher age at onset and less pro-
nounced tumor morphology, which implies that many
cases may escape detection [34,35]. Indeed, the 4 cases
with isolated loss of MSH6 and the 5 cases with com-
bined loss of MLH1/PMS2 and MSH6 developed after
age 70. Though these cases are not likely to influence
the performance of the MMR index, the observation in-
dicates that Lynch syndrome should be considered also
among somewhat older patients. The MMR index is not
intended for identification of Lynch syndrome cases and
has not been validated in younger individuals. However,
11 of 14 MSH2/MSH6 deficient tumors in our series as
well as all 7 MSH2/MSH6 deficient tumors reported by
Halvarsson et al. [25] fulfilled the criteria and would
have been detected by the MMR index.Conclusions
In summary, the MMR index provides a validated tool
to identify the MMR deficient subset of colon cancers.
Study limitations include assessment of MMR status
solely based on immunohistochemical staining and in-
clusion of a small number of presumed Lynch syndrome
tumors, which were not further genetically character-
ized. The impact from these shortcomings is judged to
be minor and also mimics applicability in clinical rou-
tine. The MMR index does, in addition to factors evalu-
ated as part of the routine diagnostic work-up (i.e. sex,
age, tumor location and occurrence of mucinous differ-
entiation) requires added evaluation only of growth pat-
tern, dirty necrosis and TIL. The simple application and
favorable reproducibility represent key advantages to-
wards its clinical implementation for identification of in-
dividuals with a favorable prognosis who may be spared
adjuvant chemotherapy.
Additional file
Additional file 1: Table S1. Distribution of clinicopathologic features in
the different prediction models for MMR (n = 200).
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